Please login to the form below

Not currently logged in
Email:
Password:

Biogen Idec names head of gene therapy

Olivier Danos joins from Kadmon Pharmaceuticals
Olivier Danos Biogen Idec

Biogen Idec has appointed Dr Olivier Danos as senior VP, gene therapy.

Dr Danos will lead Biogen Idec's gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering. Danos will also identify potential collaborations for the company.

“Olivier is a true pioneer in the field,” said Dr Douglas Williams, executive VP, R&D. “We believe that his expertise will help accelerate our development of a world-class gene therapy platform that combines our growing internal capabilities with collaborations with leading research organizations across the globe.”

Dr Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation since 2011.

Prior to Kadmon, Dr Danos acted as the director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital – Enfants Malades in Paris.

His career also includes a spell as president of the European Society of Gene and Cell Therapy.

24th September 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics